Intellipharmaceutics (IPCI) Reports Q3 Loss of $0.08/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
Go back to Intellipharmaceutics (IPCI) Reports Q3 Loss of $0.08/Share
October 9, 2015 7:00 AM EDT
TORONTO, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq: IPCI) (TSX: I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the Dawson James Securities Growth Stock Conference on October 15, 2015. The presentation will take place at 11:45 A.M. (EDT) in the Wyndham Grand Hotel in Jupiter, Florida.
The presentation may be accessed through the Investor Relations' Events and Presentations section on Intellipharmaceutics' website at... More
October 9, 2015 7:00 AM EDT
TORONTO, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2015. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
During the three months ended August 31, 2015, the Company continued its focus on the development of its specialty drug product candidates Rexista Oxycodone... More
October 9, 2015 7:00 AM EDT
TORONTO, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq: IPCI) (TSX: I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the Dawson James Securities Growth Stock Conference on October 15, 2015. The presentation will take place at 11:45 A.M. (EDT) in the Wyndham Grand Hotel in Jupiter, Florida.
The presentation may be accessed through the Investor Relations' Events and Presentations section on Intellipharmaceutics' website at... More
October 9, 2015 7:00 AM EDT
TORONTO, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2015. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
During the three months ended August 31, 2015, the Company continued its focus on the development of its specialty drug product candidates Rexista Oxycodone... More
